\
&
Contact us
\
&
Contact us
This was 3 years ago
LocationBrussels
This will be the fifth edition of the Electronic Components and Systems (ECS) Brokerage Event. This two-day get-together is the perfect way to prepare your proposals for KDT-JU calls and other ECS related calls.
The preparation of project proposals and meeting potential consortium partners will be core business. Just like last years, AENEAS, EPoSS and Inside join their forces again to create a perfect environment for ECS experts from all over Europe to come together.
On-the-spot private break-out spaces, face-to-face project idea discussions, a poster exhibition area, the ECS Brokerage Event 2023 offers a wide variety of networking opportunities. How to apply? The ECS Collaboration Tool explains how to get the best out of the event!
The ECS Brokerage Event 2023 has a limited availability and first come, first serve. More information about the programme, speakers and venue can be found on the event website.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.
